Lifestyle Asset Management Inc. Cuts Position in United Therapeutics Co. (NASDAQ:UTHR)

Lifestyle Asset Management Inc. trimmed its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.9% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 4,281 shares of the biotechnology company’s stock after selling 318 shares during the period. Lifestyle Asset Management Inc.’s holdings in United Therapeutics were worth $983,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Mariner LLC increased its stake in United Therapeutics by 8.9% during the 3rd quarter. Mariner LLC now owns 3,365 shares of the biotechnology company’s stock valued at $760,000 after purchasing an additional 275 shares in the last quarter. Natixis Advisors L.P. increased its position in shares of United Therapeutics by 56.6% during the third quarter. Natixis Advisors L.P. now owns 21,319 shares of the biotechnology company’s stock valued at $4,815,000 after acquiring an additional 7,702 shares in the last quarter. O Shaughnessy Asset Management LLC raised its holdings in United Therapeutics by 4.9% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 2,300 shares of the biotechnology company’s stock worth $520,000 after acquiring an additional 107 shares during the last quarter. Synovus Financial Corp bought a new position in United Therapeutics in the 3rd quarter valued at approximately $203,000. Finally, Caxton Associates LP purchased a new stake in United Therapeutics during the 3rd quarter valued at $213,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Price Performance

Shares of NASDAQ UTHR traded down $6.01 during midday trading on Wednesday, reaching $311.04. 281,294 shares of the stock traded hands, compared to its average volume of 497,971. The company’s 50 day moving average is $279.61 and its 200 day moving average is $245.36. United Therapeutics Co. has a one year low of $208.62 and a one year high of $325.00. The stock has a market capitalization of $13.80 billion, a PE ratio of 14.71, a P/E/G ratio of 1.40 and a beta of 0.55. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, topping the consensus estimate of $5.63 by $0.54. The company had revenue of $677.70 million during the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The firm’s revenue was up 33.7% on a year-over-year basis. During the same quarter last year, the business posted $4.86 earnings per share. On average, equities research analysts anticipate that United Therapeutics Co. will post 24.73 earnings per share for the current year.

Insider Activity at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 15,000 shares of the business’s stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $233.27, for a total transaction of $3,499,050.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $30,325.10. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $232.05, for a total value of $835,380.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at $30,166.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 15,000 shares of the stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $233.27, for a total value of $3,499,050.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $30,325.10. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 129,944 shares of company stock worth $33,580,082. Insiders own 12.50% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. boosted their price objective on shares of United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a report on Tuesday, May 21st. The Goldman Sachs Group raised their price target on United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 20th. Wells Fargo & Company raised their target price on United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $300.00 price target on shares of United Therapeutics in a research report on Thursday, May 2nd. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $312.22.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.